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the positive predictive value of the register diagnosis was 
92.9% (95% confidence interval, CI, 84.3–97.7), the false-pos-
itive rate was low (2.8%), and the sensitivity was acceptable 
(81.2%; 95% CI 71.2–88.8).  Conclusions: Our data indicate 
that this novel approach of combining diagnosis register and 
prescription register information provides a feasible and val-
id method to trace incident myasthenia patients for popula-
tion-based epidemiological studies. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Acquired autoimmune myasthenia gravis (myasthe-
nia) is a disorder of the neuromuscular junction causing 
muscle weakness and fatiguability  [1] . The rarity of my-
asthenia combined with the need of expertise to recog-
nize and correctly diagnose the disorder makes large-
scale population-based studies of myasthenia with ad 
hoc collection of data on the disorder arduous and time-
consuming. Studies based on data from automated reg-
isters that enable timely identification of large samples 
of cases are therefore increasingly being utilized in my-
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 Abstract 
 Background: We validated a new method of identifying pa-
tients with incident myasthenia in automated Danish regis-
ters for the purpose of conducting epidemiological studies 
of the disorder.  Methods: For residents of a Danish county 
(population 484,862) in 1993–2008, we identified any hospi-
tal contacts coded for myasthenia in a nationwide patient 
register and any prescriptions for pyridostigmine in the 
county prescription register. Results from an acetylcholine 
receptor antibody register were linked to the data. We veri-
fied the diagnosis by a review of medical records.  Results: 
Subjects identified in the Patient Register (n = 83) were com-
parable with individuals found in the Prescription Register
(n = 89) with regard to age and gender, but were more of -
ten seropositive (83.1 vs. 74.2%). Seropositivity increased to 
91.6% by restricting the data to individuals recorded in both 
Patient and Prescription Registers (n = 71). We found that for 
subjects identified in both Patient and Prescription Registers 
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asthenia epidemiological research  [2–5] . We wished to 
use a nationwide Danish patient register for this pur-
pose. However, in a previous Danish study that used 
hospital patient registers as a single source for case iden-
tification, the diagnosis could not be verified by medical 
record review in roughly 27% of cases registered under 
myasthenia codes  [6] . We speculated whether combin-
ing information from patient registers with information 
from other registers would improve validity. This meth-
od could be implemented in a nationwide setting with 
relative ease. This would path the way for epidemiolog-
ical studies of myasthenia that could utilize the large 
number of population-based registers available in Den-
mark  [7] .
 Pyridostigmine, an acetylcholine esterase inhibitor, is 
used in practically all patients with clinically active my-
asthenia as the first line of therapy in Denmark. We as-
sessed the validity of a diagnosis code for myasthenia in 
a Danish nationwide patient register and tested whether 
combining data from this source with prescription regis-
ter information on pyridostigmine use enhanced the va-
lidity of the diagnosis code.
 Material and Methods 
 The study focused on a geographically well-defined area of 
Denmark, the former County of Funen (population 484,862), 
henceforth referred to as the County. The department of Neurol-
ogy at Odense University Hospital (OUH) serves as the referral 
centre for patients with neurological disorders in the area, and the 
entire County is covered by a prescription register.
 Through registers we identified individuals with a myasthenia 
diagnosis code, a presented prescription of pyridostigmine, or an 
acetylcholine receptor antibody (AChRab) test result.
 We ascertained the validity of the diagnosis both indirectly, by 
linkage to Antibody Register data, and directly, by appraisal of 
medical records of potential cases of myasthenia. To increase gen-
eralizability with regard to the Patient Register myasthenia diag-
nosis, we also validated samples from other hospitals in Denmark.
 Each resident of Denmark has a permanent unique civil regis-
tration number that is provided at birth or immigration to the 
country. This enabled simple and correct linkage of 4 registers:
 (1) The Danish National Hospital Register (Patient Register) 
includes information on discharges (since 1977) and on outpa-
tient visits (since 1995) from hospitals in Denmark (population 
5.5 million)  [8] . Patient-specific data include contact dates, de-
partment and hospital code, and diagnoses coded according to 
the Danish version of the International Classification of Diseases, 
8th revision (ICD-8) from 1977 to 1993 and ICD-10 from 1994 
onwards.
 (2) The Odense University Pharmacoepidemiological Data-
base (Prescription Register) has offered complete coverage of the 
County since November 1992  [9] . For each prescription, the date 
it was presented and a full account of the dispensed product
including the anatomical therapeutic chemical code  [10] are re-
corded.
 (3) The Antibody Register was created by us by merging data 
on AChRab results from the Neuroimmunology Laboratory at 
Rigshospitalet (RH), Copenhagen University Hospital, and the 
laboratory at OUH. Both laboratories provide in-service, as well 
as analyses of blood samples from other hospitals, general practi-
tioners and privately practising neurologists. We classified indi-
viduals as ‘positive’ if a positive result was registered in either 
register at any time. The remaining individuals were classified as 
‘negative’. Within each category the earliest date of blood sam-
pling was used as the date of antibody status.
 The measurements of AChRab performed at RH (1977–2003) 
were analysed by an in-house radioimmunoassay method  [11] . 
The RH laboratory at Copenhagen University Hospital has since 
2004 used a commercial kit for  125 I-radioimmunoassay quanti-
fication of AChRabs (DLD Diagnostika GmbH, Hamburg, Ger-
many)  [12] . The OUH laboratory used another commercial kit for 
the  125 I-radioimmunoassay of AChRab (IBL-international, Ham-
burg, Germany) throughout the period 2000–2008.
 (4) The Danish Civil Registration System has since 1968 re-
corded all persons residing in Denmark with their civil registra-
tion number, a 10-digit unique and permanent identifier  [13] . The 
birth date, gender and data on residency are recorded in the reg-
ister. Aggregated data on the background population’s age and 
gender distribution were retrieved from Statistics Denmark 
(www.dst.dk).
 Identification and Validation of Potential Incident Cases of 
Myasthenia in the County 
 We identified all discharges (from 1977 to 2008) and all out-
patient visits (from 1995 to 2008) at Danish hospitals with a re-
corded primary diagnosis code for myasthenia (ICD-8: 733.9, 
ICD-10: G70.0) in the Patient Register and classified hospital con-
tacts according to department type (neurology or non-neurolo-
gy). The date of the first contact ever with a myasthenia code was 
identified for each person in the Patient Register sample. From the 
Prescription Register we retrieved all data available in the register 
from 1990 to 2008 on prescriptions for pyridostigmine (anatomi-
cal therapeutic chemical code: N07AA02) and included subjects 
that presented at least 2 prescriptions. Data from the Antibody 
Register were classified with regard to seropositivity as previous-
ly described. For individuals identified in any of the 3 registers we 
established residency status through linkage with the Civil Reg-
istration System. Individuals thus identified were classified ac-
cording to whether data were registered in the Patient Register or 
the Prescription Register. Subjects were further subdivided ac-
cording to whether they were recorded in both the Patient and the 
Prescription register, or exclusively in one of the registers (Patient 
only, Prescription only). Since we regarded the Antibody Register 
data as an indirect validation source of the other two registers, we 
did not create a separate group for subjects with positive antibod-
ies only.
 We wished to identify incident cases of myasthenia in the 
years 1993–2008. For each subject in the initial sample, we iden-
tified the index date, defined as the first registered date in the 
Patient, Prescription or Antibody Register, whichever came first. 
We included subjects if their index date was between January 1, 
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1993, and December 31, 2008. We excluded a small number of 
potential cases under 16 years of age (n = 4), since prescriptions 
issued to children in this age group were registered under one of 
their parent’s civil registration number in part of the study pe-
riod. For the remaining cases we retrieved medical records from 
the OUH.
 Case Definition 
 Medical records of all potential cases were evaluated by one of 
us (D.G.), a neurology consultant with a special interest in myas-
thenia. A diagnosis of myasthenia was considered  definite if all 3 
of the following criteria were fulfilled: (i) the recorded history and 
examination were compatible with myasthenia (weakness and fa-
tiguability), (ii) the result of at least 1 positive paraclinical test 
(antibody test results, repetitive nerve stimulation, single-fibre 
electromyogram or edrophonium test) was recorded, and (iii) al-
ternative disorders, if suspected, were ruled out by appropriate 
tests. If a diagnosis of myasthenia was stated in the medical rec-
ord, but could not be definitely confirmed or ruled out due to in-
sufficient information on one or more of the aforementioned cri-
Danish National Hospital Register Regional Prescription Register Antibody Register
(AChRab)
Myasthenia code, 1977–2008 Pyridostigmine prescriptions, 1990–2008 RH, 1985–2008 and OUH, 2000–2008
n = 1,800 n = 229 n = 9,056
Study area resident and at least one of the following:
(i) myasthenia code, or
(ii) pyridostigmine prescriptions (>1 prescription), or
(iii) positive antibodies
n = 193
Danish Civil Registration System
Vital status, residency and migration data
First registration prior to study entry
n = 68
Emigrated from study area prior to registration
n = 13
Potential myasthenia cases 1993–2008
n = 112
Positive antibodies only 
n = 11
Potential incident myasthenia cases
1993–2008
n = 101
RH = Neuroimmunology laboratory, Rigshospitalet, Copenhagen University Hospital
OUH = Odense University Hospital laboratory
 Fig. 1. Flow diagram of register-based identification of potential incident cases of myasthenia in a Danish county, 1993–2008. 
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teria, cases were classified as  possible . A diagnosis of myasthenia 
was rejected if a case could not be classified as definite or possible. 
Cases with no identifiable medical records with pertinent infor-
mation were classified as  non-evaluable .
 We also validated the diagnosis in two other samples identi-
fied exclusively from the Patient Register: one sample comprised 
all myasthenia coded contacts at any hospital in the Region of 
Southern Denmark (RSD; population 1.2 million; 4 neurology de-
partments) and the other all myasthenia coded contacts to the 
Department of Neurology, RH (myasthenia referral centre in 
Eastern Denmark; population 2.45 million). We limited the mate-
rial to potential incident cases of myasthenia as previously de-
scribed. A random sample of 100 potential cases of myasthenia 
from each region was identified for further validation. The RSD 
also includes the County, and therefore there was some degree of 
overlap between the cases in this sample and those of the main 
study.
 Statistical Analysis 
 Results were reported in numbers and percentages for categor-
ical data and median and interquartile ranges for continuous 
variables. For group comparisons we used the   2 test, Fisher’s ex-
act test and Mann-Whitney U test when appropriate. Probability 
results below 0.05 were considered statistically significant.
 The positive predictive value of a register diagnosis (PPVD) 
with 95% confidence intervals was calculated as the proportion of 
individuals having myasthenia according to register data where 
the diagnosis could be verified according to our criteria.
 The present study is part of a larger epidemiological research 
project that was approved by the Ethics Committee, RSD and the 
Danish Registry Board.
 Results 
 In all, 193 potential cases of myasthenia (diagnosis 
code of myasthenia, presented prescription of pyridostig-
mine or positive antibody test) were identified in the 
County in the study period from 1993 to 2008 ( fig.  1 ). 
Eighty-one individuals were excluded because they were 
registered before or after being eligible for the study. The 
distribution of the remaining 112 subjects among regis-
ters is presented in  figure 2 .
 The main analyses focused on the 101 potential inci-
dent cases of myasthenia recorded in the Patient or the 
Prescription Register ( fig. 1 ). Age, gender and year of first 
registration were comparable in subjects identified by ei-
ther the Patient Register (n = 83) or the Prescription Reg-
ister (n = 89;  table 1 ). Subjects identified by the Prescrip-
tion Register were less frequently seropositive (74.2%) 
and had more frequently no registered antibody test 
(16.9%) compared with subjects tracked by the Patient 
Register (83.1 and 2.4%, respectively). We could not iden-
tify any hospital contacts (discharges or outpatient visits) 
coded under myasthenia for 18 (20.2%) of the subjects 
identified in the Prescription Register.
 Various indirect markers of validity were most fre-
quent in the group of subjects identified in both registers. 
The percentage that tested seropositive (91.6%) was high-
est and the percentage with no registered antibody test 
Patient Register Antibody Register
4
8 11
65
6 1
17
Prescription Register
 Fig. 2. Potential cases of myasthenia (n = 
112) in a Danish county in 1993–2008 
identified by 3 registers. Only individuals 
presenting more than 1 pyridostigmine 
prescription were included in the Prescrip-
tion Register. 
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Table 1. Characteristics of 101 potential incident myasthenia cases in a Danish county, 1993–2008
Patient 
Regist er
(n = 83)
Prescription 
Register
(n = 89)
Patient and 
Prescription 
Register (n = 71)
Patient 
Register 
only (n = 12)
Prescription 
Register 
only (n = 18)
Female 42 (50.6) 48 (53.9) 37 (52.1) 5 (41.7) 11 (61.1)
Age at first registration1
Median, years 66.6 [50.7–76.4] 61.5 [50.3–75.3] 63.6 [51.9–76.4] 67.9 [37.1–76.3] 51.6 [43.0–60.5]
<40 years 17 (20.5) 17 (19.1) 14 (19.7) 3 (25.0) 3 (16.7)
≥40 years 66 (79.5) 72 (80.9) 57 (80.3) 9 (75.0) 15 (83.3)
Year of first registration
1993–2000 37 (44.6) 42 (47.2) 32 (45.1) 5 (41.7) 10 (55.6)
2001–2008 46 (55.4) 47 (52.8) 39 (54.9) 7 (58.3) 8 (44.4)
AChRab2
Positive 69 (83.1) 66 (74.2) 65 (91.6) 4 (33.3) 1 (5.6)
Negative 12 (14.5) 8 (9.0) 5 (7.0) 7 (58.3) 3 (16.7)
Not registered 2 (2.4) 15 (16.9) 1 (1.4) 1 (8.3) 14 (77.8)
Registered with diagnosis of myasthenia – most specialized department type ever3
Neurology 78 (94.0) 69 (77.5) 69 (97.2) 9 (75.0) n.a.
Non-neurology only 5 (6.0) 2 (2.3) 2 (2.8) 3 (25.0) n.a.
Not registered at any department n.a. 18 (20.2) n.a. n.a. n.a.
Diagnosis verified by medical records
Yes
Definite 71 (85.5) 66 (74.2) 66 (93.0) 5 (41.7) 0
Possible 3 (3.6) 7 (7.9) 3 (4.2) 0 4 (22.2)
N o 9 (10.8) 9 (10.1) 2 (2.8) 7 (58.3) 7 (38.9)
Non-evaluable 0 7 (7.9) 0 0 7 (38.9)
Results are numbers with percentages in parentheses or medians 
with interquartile ranges in square brackets. n.a. = Not applicable.
1 Age on date of the earliest of the following: registered myas-
thenia diagnosis, second presented pyridostigmine prescription 
or positive antibody test.
2 According to the Antibody Register.
3 The ‘most specialized department’ subject was seen at in- or 
outpatient examination and recorded with a primary code of my-
asthenia according to the Patient Register.
Table 2.  Reasons for rejection of register myasthenia diagnosis in the 16 false-positive cases
Patient and Pre-
scription (n = 2)
Patient only
(n = 7)
Prescription
only (n = 7)
Workup revealed that cause was other neurological disorder1 0 5 0
Myasthenia diagnosis initially suspected, but later rejected 1 0 1
Diffuse symptomatology 1 1 1
Pyridostigmine used for indication other than myasthenia2 0 n.a. 5
Coding error 0 1 0
n.a. = Not applicable. 
1 Includes the following: acute disseminated encephalomyelitis, brain stem infarction, cranial nerve affection (III or IV), Horner’s 
syndrome.
2 Given as symptomatic treatment in patients suffering from multiple sclerosis (n = 4) or subileus (n = 1).
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was lowest in this group (1.4%) (antibody test vs. groups, 
p  ! 0.001). The Prescription Register only group had the 
highest frequency of no registered antibody test (77.8%; 
 table 1 ).
 We could verify a diagnosis of definite myasthenia ac-
cording to our criteria in 85.5% of patients identified in 
the Patient Register and 74.2% of those identified in the 
Prescription Register ( table  1 ). The diagnosis could be 
verified as definite in 93.0% of subjects recorded in both 
registers, but only in 5 of 12 (41.7%) of Patient Register 
only and none of 18 of Prescription Register only subjects 
(p  ! 0.001). In the Prescription only group, however, 7 
cases (38.9%) were non-evaluable.
 We attempted to validate the diagnosis through med-
ical records for (i) all 101 subjects included in the main 
analyses, (ii) for subjects only recorded in the Antibody 
Register (n = 11) and (iii) for two categories excluded by 
our register criteria, i.e. subjects only recorded in the Pa-
tient Register under secondary myasthenia codes (n = 7) 
and subjects only recorded in the Prescription Register 
with a single prescription of pyridostigmine (n = 33). In 
most groups the number of non-evaluable subjects was 
small. However, subjects only identified by prescriptions 
were a notable exception, regardless of whether identified 
by 2 or more pyridostigmine prescriptions (7 of 18 in the 
Prescription Register only group) or only a single pre-
scription (16 of 33).
 We verified the diagnosis of myasthenia in 85 subjects 
(75 definite and 10 possible cases). These figures include 
3 definite and 1 possible case from the Antibody only 
group, 1 possible case with secondary myasthenia codes 
from the Patient Register only group, and 1 definite and 
1 possible case identified among single pyridostigmine 
prescription presenters. In the Antibody Register only 
group, the 7 non-cases comprised 2 subjects who suffered 
from amyotrophic lateral sclerosis, 3 cases that, accord-
ing to an evaluation by a neurologist with a special inter-
est in myasthenia, did not have specific complaints or 
findings compatible with this disorder, and 2 non-evalu-
able cases.
 In the 85 subjects with verified myasthenia diagnosis, 
the median age on the index date was 68.4 years (inter-
quartile range 52.7–77.5). Forty-five of the verified cases 
were women (52.4%), 72 (84.7%) were seropositive for 
AChRab, 13 (15%) had ocular myasthenia, and 6 cases 
had histology-verified thymoma (7.1%).
 Information on the year of symptom onset was avail-
able in 78 of 85 subjects (91.7%) with verified myasthenia. 
The median age at symptom onset was 66 years (inter-
quartile range 52–76), and the majority of cases had their 
onset after the age of 40 (82.4%). The female-to-male ratio 
was 4: 1 in those aged 40 years or less and 0.8: 1 in those 
aged 40 years or more at the time of symptom onset (sex 
vs. age in categories, p = 0.004). In 42 of 78 verified cases 
(53.8%), there was full agreement between the year of 
symptom onset and the year of the index date in the reg-
ister. Allowing for a difference of 1 year between symp-
tom onset and year of index date increased agreement to 
83.3% (89.7% for 2 years of difference). The correspond-
ing figures for the subsample of 68 verified cases from the 
Patient and Prescription Register group were 57.5, 81.8 
and 87.9%, respectively.
 Reasons for rejecting the register diagnosis in false-
positive cases are presented by group in  table 2 .
 PPVD in County Data 
 The PPVD when cases were tracked using the Patient 
Register as the single source was 85.5% (95% confidence 
interval, CI, 76.1–92.3) if only definite cases were includ-
ed and 89.2% (80.4–94.9) if all cases (definite and pos-
sible) were included. For the Prescription Register the 
PPVD was 72.5% (95% CI 62.2–81.4) for definite cases 
and 80.2% (70.6–87.8) for all cases. The PPVD of a diag-
nosis using the Antibody Register as a single register 
source is presented in  table 3 .
 The PPVD for patients identified in both the Patient 
Register and the Prescription Register were 92.9% (95% 
CI 84.3–97.7) for definite and 97.2% (90.2–99.7) for defi-
nite and possible cases. The combination of Patient and 
Prescription Register also performed well when com-
pared with other combinations of register sources ( ta-
ble 3 ).
 In the Patient and Prescription Register group we 
 examined the time window necessary for a subject to be 
traced in both registers. With a time window of maxi-
mum 3 months between events in the two registers we 
captured 70.4% of the subjects in the Patient and Pre-
scription group, which increased to 87.3% if a time 
 window of maximum 6 months was employed. Re-
stricting the analysis to verified cases of myasthenia 
had little influence on these results (71.0 and 86.7%, re-
spectively).
 PPVD of Patient Register – Other Samples 
 For the sample at the Neurology Department, RH, we 
could retrieve medical records for 98 out of 100 sampled 
patients. A definite diagnosis was established in 78 cases 
(PPVD of 78%; 95% CI 68.6–85.7). If the 2 possible cases 
were also included, the PPVD was 80% (70.8–87.3). In the 
sample from RSD we could retrieve medical records for 
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94 of 100 selected patients and reached a diagnosis of def-
inite in 65 cases (PPV 65%; 95% 54.8-74.3) and definite or 
possible in 73 cases (PPVD 73%; 63.2–81.4).
 Discussion 
 We found that identifying patients with myasthenia by 
linkage of a number of population-based Danish registers 
was feasible. Combining Patient Register and Prescrip-
tion Register information resulted in a high positive pre-
dictive value of the register diagnosis and acceptable sen-
sitivity. We will apply the method in future population-
based epidemiological studies of myasthenia in Denmark.
 We expect use of automated registers in myasthenia 
research to burgeon in years to come since many of these 
resources have now been in use sufficiently long to enable 
identification and follow-up of large samples of myasthe-
nia patients at relatively low cost. Probably owing to lo-
gistical and data confidentiality issues, validation of the 
register diagnoses is frequently lacking in these studies 
 [2–5] . Although differences in design make straightfor-
ward comparisons across studies difficult, we do believe 
that our study provides an impression of the validity of 
approaches used by other researchers, provided the set-
tings are comparable to ours.
 The Danish health system is highly organized with 
free access to health care. Most drugs, including pyr-
idostigmine, are subsidized by the state. Combined with 
an extensive recording of health-related issues in a large 
variety of registers, the setting has highly desirable qual-
ities for large-scale epidemiological studies. The register 
data are covered in an automated fashion making issues 
of recall bias irrelevant. The main issues to consider are 
the validity of the register diagnosis, here estimated by 
the PPVD, and the completeness of registration, i.e. the 
proportion of patients with myasthenia in the target pop-
ulation correctly classified as such by the register  [14] , 
here estimated by sensitivity.
 The validity of a Patient Register diagnosis of myas-
thenia in the County was comparable to that of RH 
(PPVD 89.2 vs. 80.0%). The lower PPVD detected in the 
sample from the RSD (73%), might, at least in part, be due 
to our inability to retrieve medical records on 6 cases 
(6%), 3 of which were registered with positive AChRab in 
the Antibody Register. Medical records were mainly re-
trieved from 5 neurology departments out of a total of 20 
neurology departments in Denmark, which included 2 of 
Table 3.  Positive predictive value of register diagnosis of myasthenia by data source
Source for case capture Potential cases
captured
evaluable2/total
Positive predictive value, % False-
positive
S ensitivity1, %
definite only definite and possible definite only definite and possible
Single register
Patient 83/83 85.5 [76.1–92.3]  89.2 [80.4–94.9] 9 (10.8) 94.7 [86.9–98.5] 87.1 [78.0–93.3]
Prescription3 82/89 72.5 [62.2–81.4]  80.2 [70.6–87.8] 9 (10.1) 88.0 [78.3–94.4] 85.9 [76.6–92.5]
Antibody4, 5 79/81 84.0 [74.1–91.2]  88.9 [80.0–94.8] 8 (9.9) 90.7 [81.7–96.2] 84.7 [75.3–91.6]
Multiple registers 
Patient and Prescription 71/71 92.9 [84.3–97.7]  97.2 [90.2–99.7] 2 (2.8) 88.0 [78.4–94.4] 81.2 [71.2–88.8]
Prescription and Antibody4 66/66 93.9 [85.2–98.3]  98.5 [91.8–99.9] 1 (1.5) 82.7 [72.2–90.4] 76.5 [66.0–85.0]
Patient and Antibody4 69/69 94.2 [85.8–98.4]  97.1 [89.9–99.6] 2 (2.9) 86.7 [76.8–93.4] 78.8 [68.6–86.9]
Patient and Prescription
and Antibody4 64/64 96.9 [89.2–99.6] 100.0 [94.4–100.0] 0 82.7 [72.2–90.4] 75.3 [64.7–84.0]
Re sults are numbers with percentages in parentheses or per-
cent with 95% CI in square brackets. 
1 Percentage of all definite (n = 75) and definite and possible 
(n = 85) verified cases in the study; includes 4 definite and 3 pos-
sible cases identified by the Antibody Register only, Patient Reg-
ister only (secondary myasthenia code) and Prescription Register 
only (1 pyridostigmine prescription only).
2 Medical records with information pertinent to evaluation of 
myasthenia cases could be retrieved.
3 Only subjects presenting 2 or more pyridostigmine prescrip-
tions in study period included.
4 Only subjects with positive antibody test included.
5 11 subjects exclusively identified by positive antibodies for 
AChR only included in this analysis.
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the 4 university hospital departments that act as referral 
centres for myasthenia. We therefore believe our results 
to be generalizable to Denmark as a whole.
 It is our experience that the vast majority of patients 
with myasthenia are referred to departments of neurol-
ogy for further workup, and that only management of 
uncomplicated myasthenia after full hospital evaluation 
is on rare occasions handed over to privately practising 
neurologists or general practitioners. Patients with undi-
agnosed myasthenia would not be captured by our meth-
od. However, we assume this scenario to be rare, espe-
cially given the long study period. We therefore believe 
that our calculations of sensitivity presented in  table  2 
provide a reasonable estimate of completeness for the Pa-
tient Register.
 Our prescription data contain no information on the 
indication for pyridostigmine use. This was particularly 
problematic in subjects identified exclusively through the 
Prescription Register. We could evaluate the indication 
for pyridostigmine use through medical records for a 
small number of patients from this group. Based on this, 
we suspect that the bulk of cases only recorded in the Pre-
scription Register represented use of pyridostigmine for 
indications other than myasthenia, or an initial loosely 
founded suspicion of myasthenia in patients where the 
diagnosis was later rejected.
 We found that combining Patient and Prescription 
Register data to a large degree overcame issues of validity 
in the County sample. There is an inherent survival bias 
when using any of the sources in combination, as op-
posed to using a single source. To be recorded in the Pa-
tient and Prescription Register for instance, the patient 
has to live long enough to be seen at the hospital  and pre-
sent a prescription. It was therefore reassuring that these 
events were separated by a time window of less than 6 
months in 87.3% of cases captured in the Patient and Pre-
scription Register group. Severe myasthenia leading to 
death shortly after presentation is extremely rare.
 The characteristics of verified myasthenia cases in the 
County sample were highly comparable to those reported 
in previous epidemiological studies with regard to age 
and gender distribution, in particular female-to-male ra-
tio within age categories, and myasthenia subtype (ocular 
vs. generalized)  [1, 15] . A small minority of myasthenia 
patients, previously classified as antibody negative, have 
been shown to have antibodies against a kinase (MUSK). 
In our experience, the incidence of MUSK-positive myas-
thenia is very low in Denmark. Therefore, lack of this in-
formation in this or future register-based Danish studies 
only represents a minor problem.
 Identifying incident cases of myasthenia is, regardless 
of method, hampered by the lag time between symptom 
onset and recognition of this rare disorder. We therefore 
find it acceptable that the year of symptom onset coin-
cided with the year of index date in roughly half the cas-
es and that the majority of remaining cases were recorded 
within a couple of years of symptom onset. This finding 
did not depend on the number or combination of regis-
ters used for case identification, which underscores that 
the problem is not inherent to the method suggested here 
of linking Patient and Prescription Register data.
 Patient Register data are routinely collected and made 
available for research at a nationwide level in Denmark. 
A national prescription database with a data structure 
and content highly reminiscent of the County Prescrip-
tion Register has recorded all prescriptions presented in 
Denmark since 1995  [9] . We believe this set-up provides 
unique opportunities for research in myasthenia that our 
method will enable us to utilize. Similar nationwide reg-
isters may provide the basis for use of this method in oth-
er countries with health systems comparable to the Dan-
ish one.
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